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Introduction
(JNK), and p38. Intrinsic and BCR-induced signals are also regulated by B lymphocyte cell-surface molecules that modify and provide a context for BCR signal transduction.l 5 These cell-surface molecules are commonly called "co stimulatory molecules" when they function in conjunction with the BCR to amplify signal transduction. However, another class of cell surface molecules are the "response-regulators" of lymphocyte signaling.15 Response-regulators carry out broader functions than costimulatory molecules since they establish intrinsic signaling thresholds that provide a context for transmembrane signals including BCR-generated signals.
We have recently suggested that CD19 and CD22 are members of the response-regulator class of cell-surface molecules. 16 ,17 CD19 and CD22 may each reciprocally regulate BCR signaling by associating directly with cellsurface IgM. [18] [19] [20] Herein this review, we propose a unique molecular mechanism through which tyrosine phosphorylated CD19 and CD22 function cooperatively to regulate a Src-family PTK activation loop that modulates intrinsic and BCR-induced signals . 21 These find ings provide a mechanistic explanation of how CD19 regulates basal signaling thresholds and accelerates BCR signaling in vivo. Increased activity of this CD19/ Src family kinase amplification loop may explain why patients and mice that overexpress CD19 are predis posed to produce autoantibodies.
CD19 and CD22 Expression Influence Autoimmunity
The production of autoantibodies is regulated by self-antigens signaling through B cell antigen receptors. These responses are further influenced by CD19, CD22 and other signal transduction molecules that function as response regulators to amplify or inhibit BCR signal ing.22 Intracellular regulatory molecules that appear to control BCR signaling intensity also include Lyn, Btk, Vav, and the SHPT protein tyrosine phosphatase.9.22. 23 Recently, we have demonstrated that CD19, CD21, CD22, Lyn, Vav, and SHP1 are functionally linked in a common signaling pathway.
Remarkably, mice with altered CD19, CD21, CD22, Lyn or SHP1 expression produce autoantibodies and develop autoimmunity to varying degrees. Peripheral tolerance is disrupted in mice that overexpress CD19, which results in the spontaneous production of IgG subclass autoantibodies.24.25 Self-reactive B cells deficient in CD21 expression are not anergized by soluble self-antigen in mouse models of tolerance.26 CD22 de fi ciency is sufficient to predispose to development of high affinity autoantibodies in mice.27 Lyn-deficient mice exhibit glomerulonephritis due to the presence of immune complexes containing autoantibodies. 28 ing molecules at normal levels, BCR ligation induces only modest phosphorylation and activation of downstream signaling molecules.21 Thereby, CD19-deficient mice generate modest humoral immune responses. 24, 32, 46, [48] [49] [50] B cells from transgenic mice that overexpress CD19 mature normally within the periphery.46,47 However, these B cells are hyper-responsive to transmembrane signals, proliferate at elevated levels, and generate ele vated humoral immune responses.24,32,49,50 Although these transgenic mice overexpress human CD19, human and mouse CD19 proteins appear functionally equiva lent in vivo. 32 The effects of CD19 overexpression and resultant hyperactivity are diverse and dramatic. For example, there is a >95% reduction in the number of B cells exiting the bone marrow and entering the circulating B cell pool, presumably the result of enhanced negative selection during development. Similarly, B cells from mice that overexpress CD19 are hyperproliferative following mitogen stimulation ex vivo. Thus, CD19 functions as a general response-regulator or rheostat that functions independent of BCR ligation, which defines signaling thresholds critical for expansion of the peripheral B cell pool. 15, 17 While both the costimulatory molecule and responseregulator models of CD19 function are synergistic, they imply different regulatory roles for CD19 (Fig. 2) . That the majority of mature B cells are affected by loss or overexpression of CD19 suggests that CD19 regulates B cell function independent of BCR engagement, but In vitro studies examining tyrosine phosphorylation sites within recombinant CD19 have offered an explanation for the paradox outlined above. 56 These studies demonstrate that CD19 has two preferential Lyn phosphorylation sites when presented as peptides: Y391 and Y513, although other residues are phosphorylated at lower levels. However, the phosphorylation pattern is different for an intact CD19 cytoplasmic domain. We therefore propose that the CD19 cytoplasmic domain is highly folded due to its multiple highly-charged regions. 66 In its folded state, CD19-Y513 is likely to be the preferential Lyn phosphorylation site following BCR engagement and Lyn activation (Fig. 3A,B) , and then phosphorylated Y513 acts as a nucleation site to retain Lyn through its SH2 domain (Fig. 3B) . Phosphorylated CD 19-Y513 is the preferred Lyn binding site among CD19 phosphotyrosine motifs. CD19-Y513 phosphorylation may "unfold" the CD19 cytoplasmic domain and thereby allow other tyrosines to be phosphorylated (Fig. 3C) . The C-terminal location of CD19-Y513 as a preferred Lyn phosphorylation and binding site is consistent with a model of "processive phosphorylation". Processive phosphorylation is where a C-terminal SH2 domain binding site in target substrates enhances Src-family PTK phosphorylation of N-terminal tyrosines.67 A CD19 fusion protein lacking an intact Y513 residue is not phosphorylated by Lyn during in vitro assays, demonstrating a requirement for CD 19-Y513 phosphorylation for subsequent phosphorylation of other residues. Phosphorylation of a CD19-Y482F mutant of CD19 exon 12-14 fusion protein is markedly reduced during in vitro kinase assays compared with an intact exon 12-14 protein, further ver ifying that CD 19-Y482 is a Lyn phosphorylation site after phosphorylation and binding to Y513 Thus, Lyn may phosphorylate more proximal N-terminal CD19 tyrosines, including Y482 and Y391, through processive phosphorylation after CD19-Y513 phosphorylation and binding. CD19 amplifies Lyn activity by "processive amplification"
The recent finding that Lyn interactions with CD19 directly amplify Lyn activation provides a new understanding of CD19 function and explains many of the 
CD19 binding amplifies Lyn phosphorylation of Vav
In addition to amplifying Src-family PTK activity, CD19 also facilitates molecular interactions that lead to Vav phosphorylation, which is decreased in CD19-deficient B cells.65 Vav binds phosphorylated CD19 tyrosine residues directly via its SH2 domain. The primary binding site for Vav is Y391 but Vav also interacts with Y421, and weakly with Y403 and Y513 (Fig. 1) (Fig. 3F) . The generation of CD19/CD22-double deficient mice has provided additional insight into the cross-regulation between CD19 and CD22 on B cell signaling.81 Func tional studies of CD19/CD22-deficient B cells have revealed that CD19-deficiency is dominant in CD19/ CD22-deficient mice, rather than CD19-and CD22-deficiencies having additive effects. BCR-induced tyrosine phosphorylation of total cellular proteins is equally impaired in CD19/CD22-deficient and CD19-deficient B cells, regardless of CD22 expression. Of significance, Lyn kinase activity is only modestly increased in CD19-deficient and CD19/CD22-deficient B cells after BCR ligation. Furthermore, Vav tyrosine phosphorylation following BCR ligation is decreased to a similar extent in CD19/CD22-deficient B cells and CD19-deficient B cells. Mitogen-induced proliferation of CD19/CD22-deficient B cells is reduced to levels identical with CD19-deficient B cells. Despite reduced proliferation by CD22-deficient B cells in response to IgM ligation, the combined loss of CD19 and CD22 does not affect proliferation beyond the effect of CD19 loss alone. Serum Ig levels in CD19/CD22-deficient and CD19-deficient mice are identical, as are antibody responses to T-dependent antigen immunization. Spleen B cell numbers in CD19/CD22-deficient mice are reduced as in CD19-deficient mice. As occurs in CD19-deficient mice, B1 cells within the peritoneum of CD19/CD22-deficient mice are rare, despite increased 131 cell num bers in CD22-deficient mice. 86 
Conclusions
Studies of CD19 have provided novel insights into normal and autoimmune B cell function. These studies suggest that intrinsic signal transduction thresholds regulated by CD19 are a pivotal element in autoantibody production. The generation of a Src-family PTK amplification loop by CD19 represents a novel mecha nism for regulating intracellular signal transduction thresholds in addition to its previously hypothesized role as a specialized adapter protein for recruiting sig naling effector molecules to the cell surface.22,44 CD19 amplification of Src-family PTK function also provides additional insight into why CD19 supplies potent costimulatory function when co-ligated with the BCR complex. That CD19 is associated with both Lyn and These studies unite the previous concept that CD19, CD21, CD22, Lyn, Vav and SHP1 are involved in the regulation of B lymphocyte signal transduction thresh olds and show that each of these molecules contributes to a CD19-regulated pathway. Undoubtedly each mol ecule also contributes to other pathways. For example, although synergistic interactions between Lyn and CD19 amplify basal and BCR-induced signal trans duction, the phenotype of CD19-deficient mice con trasts with that of Lyn-deficient mice, which are auto immune. 28,29.46,48,100 This may result in part from CD19 expression being B cell-restricted, while Lyn is expressed broadly within hematopoietic tissues. Lyndeficiency also leads to exaggerated inflammatory stim uli that may contribute to autoimmunity since Lyn negatively regulates cytokine signaling in macrophages through its ability to phosphorylate inhibitory recep tors.5 Nonetheless, Lyn and CD19 have both positive and negative roles in BCR-mediated signal transduction.5,15 For example, signal termination following activation of the CD22 inhibitory pathway is a critical function for Lyn.28.29,100 Lyn is responsible for CD22 phosphorylation,7 while CD22 phosphorylation and function is upregulated by CD19 expression as well.65,81 Therefore, we propose that C1319-mediated amplification of the Src-family PTK pathway is required for initiating the down-regulatory functions of CD22. Remarkably, CD19 is a major target for the downregulatory functions of CD22.Sr Thereby, CD19 expres sion synergistically modulates the positive and negative roles of Lyn, although Lyn regulates other pathways as well. Furthermore, CD19 may only modulate the acti vation of a specialized pool of intracellular Lyn kinase since the majority of intracellular Lyn did not associated with CD19. Whether CD19 and the BCR com plex share the same small pool of cellular Lyn is unknown. CD19 may also regulate the activation of other Src-family PTK members since Fyn and Blk tyrosine phosphorylation are diminished in CD19-deficient B cells.21 Thus, the collective phenotypes of Lyn-deficient and CD19-deficient mice are likely to reflect multiple qualitative and quantitative factors which account for their differences.
The identification of a subset of patients that overexpress CD19 and the demonstration that similar CD19 overexpression in mice leads to the production of autoantibodies suggests that the CD19 signaling pathway contributes to human disease. This also establishes a new paradigm by which very subtle changes in expres sion or function of tightly regulated signal transduction molecules may predispose to autoimmunity. Since mul tiple signaling molecules (CD19, CD21, CD22, Lyn, Vav and SHP1) appear to contribute to a common sig naling pathway it is possible that subtle alterations in the expression or function of any of these molecules could induce pathology. In a broader sense, any alter ation that disrupts the normal balance of signal trans duction in resting or activated B cells may also predis pose to autoimmunity.9 A further understanding of how B lymphocyte signaling thresholds are regulated at the molecular level will undoubtedly reveal additional autoimmunity susceptibility genes that function at the cell surface and within the cytoplasm. The further chal lenge will be to understand how these molecules inter act and how combinations of subtle alterations interact to cause the different manifestations of autoimmune disease.
